Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study published ...

Dupilumab significantly reduces severe exacerbations and improves lung function in children with moderate-to-severe type 2 ...

AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.

Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.

Earlier this year, researchers of Brigham and Women’s Hospital Harvard Medical School looked at clinical trials to show how six biologics, in particular, improve lung function; cut down on steroid use ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

Mepolizumab, a biologic approved for asthma, is not currently approved for COPD, but data from a 2017 study showed a trend ...

The Bergendorff scholarship was founded in 2022 in honor of Anders Bergendorff, the former program director of the master ...

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms ...

Efficacy of Medication in Young Children with Atopic Dermatitis: Study FindsResearch at National Jewish Health and other ...

Upstream Bio's verekitug targets severe asthma, CRSwNP, and COPD, with promising early phase 2 data expected in 2025 and 2026 ...

Chronic exposure to irritants, allergens, and repetitive hand washing are established risk factors for chronic hand eczema.